• Explore /
  • Poster
  • / Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).

Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Jemma Buchalter

Mater Misericordiae University Hospital, Dublin, Ireland

Jemma Buchalter , Iseult Browne , Colm Mac Eochagain , Calvin Flynn , Hailey Kathryn Carroll , Marie Galligan , Michele Bourke , Amy Lester-Grant , Fiona Desmond , Katherine Hoey , Ronan Ryan , Colin P Cantwell , Jeffrey McCann , Ray McDermott , Ross MacNicholas , Austin G Duffy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

2019-002767-98

DOI

10.1200/JCO.2022.40.4_suppl.451

Abstract #

451

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hailey Kathryn Carroll

First Author: Sung-Hua Chiu

First Author: Ghassan K. Abou-Alfa

First Author: Chi Leung Chiang